TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - JOHNSON & JOHNSON Stock

Certificat

DE000SW1F8Q3

Delayed Deutsche Boerse AG 11:35:15 2024-05-24 am EDT
17.14 EUR +0.18% Intraday chart for TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - JOHNSON & JOHNSON
Current month-4.25%
1 month-1.44%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-05-24 17.14 +0.18%
24-05-23 17.11 +2.03%
24-05-22 16.77 -0.83%
24-05-21 16.91 +0.36%
24-05-20 16.85 +1.14%

Delayed Quote Deutsche Boerse AG

Last update May 24, 2024 at 11:35 am EDT

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying JOHNSON & JOHNSON
IssuerLogo Issuer Société Générale Société Générale
WKN SW1F8Q
ISINDE000SW1F8Q3
Date issued 2023-07-25
Strike 334.4 $
Maturity Unlimited
Parity 10 : 1
Emission price 15.1
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 18.11
Lowest since issue 14.67
Spread 0.01
Spread %0.06%

Company Profile

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Sector
-
More about the company

Ratings for Johnson & Johnson

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Johnson & Johnson

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
149.7 USD
Average target price
172.5 USD
Spread / Average Target
+15.24%
Consensus